Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

被引：0
|
作者：
K Miller
J W Moul
M Gleave
K Fizazi
J B Nelson
T Morris
F E Nathan
S McIntosh
K Pemberton
C S Higano
机构：
[1] Charité–Universitätsmedizin Berlin,Department of Urology
[2] Duke Cancer Institute,Division of Urology, Department of Surgery and Duke Prostate Center
[3] Duke University Medical Center,Department of Urology
[4] Vancouver Prostate Center,undefined
[5] University of British Columbia,undefined
[6] Institut Gustave Roussy,undefined
[7] University of Paris Sud,undefined
[8] University of Pittsburgh School of Medicine,undefined
[9] AstraZeneca,undefined
[10] AstraZeneca Pharmaceuticals LP,undefined
[11] Fred Hutchinson Cancer Research Center,undefined
[12] University of Washington School of Medicine,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2013年 / 16卷
关键词：
zibotentan; ZD4054; non-metastatic; castration-resistant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：187 / 192
页数：5
相关论文
共 50 条
  • [41] PROSPER: A phase 3 study of enzalutamide (ENZA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
    Tombal, B.
    Hussain, M.
    Fizazi, K.
    Saad, F.
    Rathenborg, P.
    Shore, N. D.
    Demirhan, E.
    Modelska, K.
    Phung, D.
    Krivoshik, A.
    Sternberg, C. N.
    SWISS MEDICAL WEEKLY, 2018, 148 : 15S - 15S
  • [42] A new androgen receptor antagonist Darolutamide for patients with non-metastatic castration-resistant prostate cancer
    Kesch, C.
    Hadaschik, B. A.
    UROLOGE, 2019, 58 (10): : 1217 - 1218
  • [43] Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
    Paul Monk
    Glenn Liu
    Walter M. Stadler
    Susan Geyer
    Ying Huang
    John Wright
    Miguel Villalona-Calero
    James Wade
    Russell Szmulewitz
    Shilpa Gupta
    Amir Mortazavi
    Robert Dreicer
    Roberto Pili
    Nancy Dawson
    Saby George
    Jorge A. Garcia
    Investigational New Drugs, 2018, 36 : 919 - 926
  • [44] Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study
    Sun, Yinghao
    Zou, Qing
    Sun, Zhongquan
    Li, Changling
    Du, Chuanjun
    Chen, Zhiwen
    Shan, Yuxi
    Huang, Yiran
    Jin, Jie
    Ye, Zhang Qun
    Xie, Liping
    Lin, Guowen
    Feng, Yi
    De Porre, Peter
    Liu, Weiping
    Ye, Dingwei
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (05) : 404 - 411
  • [45] Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
    Monk, Paul
    Liu, Glenn
    Stadler, Walter M.
    Geyer, Susan
    Huang, Ying
    Wright, John
    Villalona-Calero, Miguel
    Wade, James
    Szmulewitz, Russell
    Gupta, Shilpa
    Mortazavi, Amir
    Dreicer, Robert
    Pili, Roberto
    Dawson, Nancy
    George, Saby
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 919 - 926
  • [46] A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer
    Dreicer, Robert
    Garcia, Jorge
    Rini, Brian
    Vogelzang, Nicholas
    Srinivas, Sandy
    Somer, Bradley
    Shi, Peipei
    Kania, Marek
    Raghavan, Derek
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) : 1044 - 1050
  • [47] Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)
    Armstrong, Andrew J.
    Kaboteh, Reza
    Carducci, Michael A.
    Damber, Jan-Erik
    Stadler, Walter M.
    Hansen, Mats
    Edenbrandt, Lars
    Forsberg, Goran
    Nord, Orjan
    Pili, Roberto
    Morris, Michael J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (08) : 1308 - 1316
  • [48] A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer
    Robert Dreicer
    Jorge Garcia
    Brian Rini
    Nicholas Vogelzang
    Sandy Srinivas
    Bradley Somer
    Peipei Shi
    Marek Kania
    Derek Raghavan
    Investigational New Drugs, 2013, 31 : 1044 - 1050
  • [49] CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
    Smith, Matthew Raymond
    Agarwal, Neeraj
    Todenhofer, Tilman
    Piulats, Josep M.
    Lee, Jae-Lyun
    Trepiakas, Redas
    Rao, Arpit
    Horvath, Lisa
    Lithio, Andrew
    Johnston, Erica L.
    Hulstijn, Maarten
    Nacerddine, Karim
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [50] Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study
    Malone, Shawn
    Wallis, Christopher J. D.
    Lee-Ying, Richard
    Basappa, Naveen S.
    Cagiannos, Ilias
    Hamilton, Robert J.
    Fernandes, Ricardo
    Ferrario, Cristiano
    Gotto, Geoffrey T.
    Morgan, Scott C.
    Morash, Christopher
    Niazi, Tamim
    Noonan, Krista L.
    Rendon, Ricardo
    Hotte, Sebastien J.
    Saad, Fred
    Zardan, Anousheh
    Osborne, Brendan
    Chan, Katherine F. Y.
    Shayegan, Bobby
    BJUI COMPASS, 2022, 3 (05): : 383 - 391
12345